BrightHeart has gained a further 510(k) clearance from the US Food and Drug Administration (FDA) for its AI-based prenatal congenital heart defect (CHD) screening platform. Building on the initial FDA ...
PARIS, May 06, 2025--(BUSINESS WIRE)--BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, announced today the 510(k) clearance for updates ...
PARIS--(BUSINESS WIRE)--BrightHeart, a leading AI innovator in obstetric and pediatric cardiology technology, announces it has received FDA 510(k) clearance for its first artificial intelligence ...
BrightHeart’s AI-based software for prenatal congenital heart defect (CHD) screening has demonstrated promise in two new ...
Paris, France – January 31, 2025, BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral ...
PARIS--(BUSINESS WIRE)--BrightHeart, a Paris-based company developing an AI solution for the prenatal detection of congenital heart defects, announced today the appointment of Michael Butchko as an ...
BrightHeart, a pioneer in AI-driven prenatal ultrasound evaluation, today announced the publication of its landmark study in Obstetrics & Gynecology, commonly known as the Green Journal. The study, ...
BrightHeart Announces €2 Million in Seed Financing from Sofinnova Partners to Improve the Detection of Fetal Heart Abnormalities PARIS, FRANCE / ACCESSWIRE / May 31, 2023 / BrightHeart, a Paris-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback